ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental injection aims to tackle root cause of rare liver disease
Disease control CompletedThis small, early-stage study tested an investigational drug called fazirsiran in people with liver disease caused by Alpha-1 antitrypsin deficiency. Sixteen participants received multiple injections under the skin to see if the drug could safely reduce the harmful protein that b…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New shot targets root cause of rare liver disease
Disease control CompletedThis study tested an investigational injection called fazirsiran in 40 people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause liver disease. The main goal was to see if the drug was safe and if it could reduce the levels of a harmful protein that bu…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First human tests begin for potential Alpha-1 treatment
Knowledge-focused CompletedThis early-stage study tested the safety of an experimental drug called ARO-AAT in 45 healthy volunteers. Researchers wanted to understand how the body processes the drug and whether it affects levels of the Alpha-1 protein. The study focused on identifying side effects and deter…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Knowledge-focused
Last updated Apr 02, 2026 02:11 UTC